4. Issues of Ethnopharmacology in HIV Management
Hepatitis C Virus
HIV-positive individuals are disproportionately affected by hepatitis infection, with approximately one-third also coinfected with hepatitis B virus (HBV) or hepatitis C virus (HCV), both of which can cause chronic illness and death. [CDC HIV and hepatitis] Hepatitis progression is more rapid among HIV-positive persons, and those infected with both viruses experience greater liver-related health problems than HIV-negative persons. HCV infection is transmitted via contact with the blood of an infected person, primarily through:
- Sharing contaminated needles, syringes, or other drug injection equipment
- Less commonly, through sexual contact with an infected person, birth to an infected mother, and needle sticks or other sharp instrument injuries
Key facts about HIV/HCV coinfection include:
- Approximately 25% of HIV-infected individuals in the United States are coinfected with HCV.
- Approximately 80% of HIV-positive injection drug users (IDUs) are HCV-coinfected.
- HIV coinfection more than triples the risk for liver disease, liver failure, and liver-related death from HCV.
- Chronic HCV infection is often silent—ie, many individuals can have the infection for 20 to 30 years without experiencing symptoms or feeling ill.
- The prevalence rate of HCV infection among African Americans is twice that among whites.
HCV infection typically has been treated with a combination of interferon and ribavirin. In May 2011, the Food and Drug Administration (FDA) approved 2 protease inhibitors for treating chronic HCV infection: boceprevir (Victrelis®) and telaprevir (Incivek®). Managing HIV/HCV coinfection is challenging, and should be done only by practitioners with expertise managing both HIV and hepatitis. (Providing culturally competent care for HIV/HCV-coinfected patients will be the subject of an upcoming curriculum.)
Pharmacogenomic concerns. Because the antiviral agent ribavirin is one of the mainstays in the treatment of HCV infection, polymorphisms that affect its metabolism—and therefore the drug’s dosing and plasma concentration—can play an important role in the efficacy of HCV treatment. Human equilibrative nucleotide transporter1 (hENT) is a major transport protein involved in the uptake of ribavirin into cells. SLC29A1 is the gene that produces hENT; genetic polymorphisms in SLC29A1 affect the expression of hENT and therefore also the cellular uptake of ribavirin. -706 G>C polymorphism affects the expression of the SLC29A1 gene and is present in 21% of whites but only 5% of African-Americans. Two polymorphisms were found only in African-Americans, -1345C>G and -1050G>A with allele frequencies of 8% and 19%. [Myers 2006, Morello 2010]